Cost effectiveness of rapid access to assessment and treatment model of care: Targeted hepatitis C clinics

Mangalore, R. P., Tallis, C., Stuart, K. A., Black, M., Whitty, J., Hewson, K. and Holtmann, G. (2013). Cost effectiveness of rapid access to assessment and treatment model of care: Targeted hepatitis C clinics. In: Australian Gastroenterology Week 2013, Melbourne Australia, (175-175). 7-9 October 2013. doi:10.1111/jgh.12365_14

Author Mangalore, R. P.
Tallis, C.
Stuart, K. A.
Black, M.
Whitty, J.
Hewson, K.
Holtmann, G.
Title of paper Cost effectiveness of rapid access to assessment and treatment model of care: Targeted hepatitis C clinics
Conference name Australian Gastroenterology Week 2013
Conference location Melbourne Australia
Conference dates 7-9 October 2013
Journal name Journal of Gastroenterology and Hepatology   Check publisher's open access policy
Place of Publication Richmond, Australia
Publisher Wiley-Blackwell Publishing Asia
Publication Year 2013
Sub-type Published abstract
DOI 10.1111/jgh.12365_14
Open Access Status
ISSN 0815-9319
Volume 28
Issue S2
Start page 175
End page 175
Total pages 1
Language eng
Formatted Abstract/Summary
Background: One of the key pillars of the Commonwealth Governments 3rd National Hepatitis C Virus (HCV) strategy is to improve patient access to antiviral treatment (AVT). The Rapid Access to Assessment and Treatment (RAAT) model of care involves streamlining HCV patients with mild fibrosis to dedicated clinics where they are assessed by a consultant hepatologist followed by subsequent investigations including standard laboratory tests, abdominal ultrasound and transient elastography (TE).

Aims and Methods: The study compared the efficiency of the RAAT model of care to historical HCV controls treated in a General Liver Clinic (GLC) in treatment of patients with chronic HCV infection. We conducted a retrospective review of 13 HCV patients first seen in general Hepatology clinics in 2008 who had a liver biopsy. These historical HCV patients were matched for age, gender and fibrosis stage with 28 HCV patients treated in 2012 under the RAAT model. Patient demographics, clinical and laboratory data were collected from patient medical records. The median number of patient attendances from first medical visit to initiation of AVT and the time to treatment in days was analysed.

Results: The mean (± SD) age was 49.5 ± 6.6, 60.9% were male and 49% were Genotype 1 and 51% were Genotypes 2/3. There was no significant difference between the two cohorts in terms of requirement for psychology review or treatment prior to AVT (38.5% GLC vs. 35.7%RAAT), fibrosis stage on liver biopsy or TE and presence of other co-morbidities. Cirrhosis was found in 7% in both groups and 93% of the patients were treatment naïve.

Conclusions: The RAAT model of care results in a significant decrease in number of visits and time to initiation of AVT. In time, this is likely to result in improved access to AVT for HCV patients. The efficiency of the RAAT model of care is likely to result in significant cost savings. Cost-analysis studies are required to confirm the cost effectiveness of the RAAT model.
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Conference Paper
Collection: School of Pharmacy Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Wed, 12 Mar 2014, 09:08:02 EST by System User on behalf of School of Pharmacy